Regulatory milestones

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) was off $0.80 to $24.91 Christmas week after FDA approved Juxtapid lomitapide to treat patients with homozygous familial hypercholesterolemia (hoFH). Juxtapid was approved with a REMS and a boxed warning for hepatotoxicity. The drug is also under review for the indication in Europe, with a decision expected in mid-2013.